Posted by: drchasrani on: June 14, 2012
A study found that tripling the standard dose of clopidogrel was able to overcome genetic resistance to the drug. No major untoward effects were seen during the study. […]
Posted by: admin on: February 28, 2012
Preventing a second episode of Cerebrovascular event and staying healthy and longer in high risk patients is the key to these guidelines given on Nov 3,2011 in GlobeNewswire via COMTEX. Team@CMHF
Posted by: admin on: November 28, 2011
Anti platelet agents are important to prevent CVD. Recent study suggests that low on-clopidogrel platelet reactivity linked to reduced CV event risk. Team@CMHF
Posted by: admin on: November 16, 2011
Tricagrelor a platelet aggregation inhibitor used in ST elevation coronary syndrome is being compared to clopidogrel in its use in ACS without ST elevation. Here is the study proving it to be even better than clopidogrel. Team@CMHF
Posted by: admin on: October 18, 2011
The American College of Cardiology Foundation and American Heart Association (ACCF/AHA have updated their guidelines for the management of patients with peripheral artery disease (PAD), emphasizing the expanded use of ankle-brachial index (ABI) measurements for earlier diagnosis, increased attention on getting patients to quit smoking, and better use of antiplatelet and other antithrombotic medications. -Team@CMHF